908 Devices
MASSNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $9.99 Prior regular-session close from the quote source.
- $9.94–$10.69 Regular-session low and high so far today.
- 534.4K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $5.03–$13.35 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own MASS if 908 Devices is a small, still-unproven bet that urgent chemical analysis moves out of centralized labs and into purpose-built handheld devices fast enough to overcome continuing operating losses.
MASS price history
Loading recent earnings…
Investment thesis
What must happen next
Customers with urgent chemical-identification needs will keep shifting analysis closer to the point of action because 908 Devices’ handheld format reduces the delay and complexity of traditional lab-based testing.HoldingMateriality: High
FY2025 GAAP annual revenue was $56.2 million, up from $47.7 million in FY2024, showing renewed conversion of demand into sales. If this behavior change continues, the company has a real demand engine; if customers revert to labs or incumbent field tools, revenue growth remains lumpy and niche.
Watch: Public-safety, forensics, or life-science customers standardize on centralized laboratory testing because accuracy, chain-of-custody, or regulatory confidence outweighs speed.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 GAAP annual revenue was $56.2 million, up from $47.7 million in FY2024, showing renewed conversion of demand into sales.
Open source ↗908 Devices’ differentiation must remain strong enough that customers pay for specialized handheld analytical capability rather than forcing the company into commodity instrument pricing.StrengtheningMateriality: High
FY2025 GAAP annual gross profit was $28.4 million on $56.2 million of revenue, implying a gross margin of about 50.6%. Durable gross margin is the bridge from attractive technology to a business model that can eventually fund its own R&D and sales effort.
Watch: Large analytical-instrument companies bundle competing field devices with service contracts or broader lab platforms, pressuring 908 Devices’ pricing.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 GAAP annual gross profit was $28.4 million on $56.2 million of revenue, implying a gross margin of about 50.6%.
Open source ↗The company’s operating model must show that growth can be added without proportional increases in R&D, selling, and support costs, otherwise the technology will not translate into durable equity value.HoldingMateriality: Medium
FY2025 GAAP annual operating loss improved to $39.4 million from a $57.4 million loss in FY2024. This determines whether shareholders own a scalable instrument platform or a cash-consuming product company that needs repeated financing.
Watch: Each new market requires expensive direct selling, application support, regulatory validation, or customization, preventing scale economies.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 GAAP annual operating loss improved to $39.4 million from a $57.4 million loss in FY2024.
Open source ↗The balance sheet must give 908 Devices enough runway to prove adoption and operating leverage before dilution or financing pressure controls strategic choices.HoldingMateriality: Medium
Cash was $70.5 million at FY2025 year-end, up from $44.0 million at FY2024 year-end. A cash runway turns an unprofitable growth thesis into an option; a shrinking runway transfers value from existing shareholders to future capital providers.
Watch: Cash burn accelerates because sales cycles lengthen, inventory builds, or support costs rise faster than revenue.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $70.5 million at FY2025 year-end, up from $44.0 million at FY2024 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Customers with urgent chemical-identification needs will keep shifting analysis closer to the point of action because 908 Devices’ handheld format reduces the delay and complexity of traditional lab-based testing. If this behavior change continues, the company has a real demand engine; if customers revert to labs or incumbent field tools, revenue growth remains lumpy and niche.
908 Devices’ differentiation must remain strong enough that customers pay for specialized handheld analytical capability rather than forcing the company into commodity instrument pricing. Durable gross margin is the bridge from attractive technology to a business model that can eventually fund its own R&D and sales effort.
The company’s operating model must show that growth can be added without proportional increases in R&D, selling, and support costs, otherwise the technology will not translate into durable equity value. This determines whether shareholders own a scalable instrument platform or a cash-consuming product company that needs repeated financing.
The balance sheet must give 908 Devices enough runway to prove adoption and operating leverage before dilution or financing pressure controls strategic choices. A cash runway turns an unprofitable growth thesis into an option; a shrinking runway transfers value from existing shareholders to future capital providers.
All standing thesis claims
Original report summary
908 Devices is a small, still-unproven bet that urgent chemical analysis moves out of centralized labs and into purpose-built handheld devices fast enough to overcome continuing operating losses.
Bull case and bear case
Bull case and bear case for 908 Devices
Where the evidence on 908 Devices stands: Holding on the latest evidence (Nov 9, 2026). Of its 4 thesis points, 1 strengthening and 3 holding.
Bull case: what the evidence supports
Customers with urgent chemical-identification needs will keep shifting analysis closer to the point of action because 908 Devices’ handheld format reduces the delay and complexity of traditional lab-based testing.
908 Devices’ differentiation must remain strong enough that customers pay for specialized handheld analytical capability rather than forcing the company into commodity instrument pricing.
The company’s operating model must show that growth can be added without proportional increases in R&D, selling, and support costs, otherwise the technology will not translate into durable equity value.
The balance sheet must give 908 Devices enough runway to prove adoption and operating leverage before dilution or financing pressure controls strategic choices.
Bear case: what would count against it
Public-safety, forensics, or life-science customers standardize on centralized laboratory testing because accuracy, chain-of-custody, or regulatory confidence outweighs speed.
Large analytical-instrument companies bundle competing field devices with service contracts or broader lab platforms, pressuring 908 Devices’ pricing.
Each new market requires expensive direct selling, application support, regulatory validation, or customization, preventing scale economies.
Thesis-Break Engine
Thesis-break watch · 908 Devices
Loading the break-condition record for 908 Devices.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
908 Devices filed an SEC 8-K on 2026-08-11: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedOther material event.
908 Devices filed an SEC 8-K on 2026-07-08: Other material event. It is a dated development that tests the current thesis.
- MixedCompleted an acquisition or disposition of assets.
908 Devices filed an SEC 8-K on 2026-05-06: Completed an acquisition or disposition of assets. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Public-safety, forensics, or life-science customers standardize on centralized laboratory testing because accuracy, chain-of-custody, or regulatory confidence outweighs speed.
- Large analytical-instrument companies bundle competing field devices with service contracts or broader lab platforms, pressuring 908 Devices’ pricing.
- Each new market requires expensive direct selling, application support, regulatory validation, or customization, preventing scale economies.
- Cash burn accelerates because sales cycles lengthen, inventory builds, or support costs rise faster than revenue.
MASS news
Loading headlines…
Financial statements
MASS income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
MASS: quick answers
- Which well-known investors own MASS?
- 1 of the 37 well-known funds tracked here reported MASS shares in their latest 13F filing. By share of the fund's portfolio: ARK Investment Management (Cathie Wood), 0.1%. Fund portfolios
MASS in well-known investors’ portfolios
1 of 37 funds reported MASS shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Cathie WoodARK Investment Management | 0.11% | $17.6M | +4.2% | Q2 2026 |